HIV/AIDS Opportunistic Infection
Oral CMV therapy cost effective
Published in AIDS Weekly, February 9th, 2004
"The overall costs usually are lower for the oral route of administration than for the intravenous route, although the cost to the patient depends on insurance coverage," pharmacists in the United States explained. "Other advantages of the oral route include greater safety and convenience, which may improve patient adherence and quality of life."
"In patients with acquired immunodeficiency syndrome (AIDS), the use of oral ganciclovir instead of intravenous ganciclovir to treat the maintenance phase of CMV retinitis reduced the incidence of neutropenia and sepsis, outpatient and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2004-02-09)
More Articles from AIDS Weekly
- Drug Development
Liminoids strongly inhibit HIV protease activity - AIDS Therapy
IND application filed for protease inhibitor GS 9005 - AIDS Treatment
AIDS activists fight for more affordable drugs - AIDS and HIV
Gene product restricts HIV-1 replication in resting CD4+ lymphocytes - Cytomegalovirus
RNAi program initiated to develop therapies for diseases associated with CMV - Education
Agreement to admit HIV-positive children into Nairobi's public schools approved - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
